Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AR | P10275 | 8/20 | 0.33 |
| ▸ | RHEB | Q15382 | 1/20 | 0.33 |
| ▸ | S1PR1 | P21453 | 2/20 | 0.33 |
| ▸ | ESR1 | P03372 | 1/20 | 0.33 |
| ▸ | MGLL | Q99685 | 1/20 | 0.32 |
| ▸ | NR1H2 | P55055 | 1/20 | 0.32 |
| ▸ | NR1H3 | Q13133 | 1/20 | 0.32 |
| ▸ | MAPT | P10636 | 1/20 | 0.32 |
| ▸ | PSEN1 | P49768 | 2/20 | 0.32 |
| ▸ | PSEN2 | P49810 | 2/20 | 0.32 |
| ▸ | APH1B | Q8WW43 | 2/20 | 0.32 |
| ▸ | NCSTN | Q92542 | 2/20 | 0.32 |
| ▸ | APH1A | Q96BI3 | 2/20 | 0.32 |
| ▸ | PSENEN | Q9NZ42 | 2/20 | 0.32 |
| ▸ | CDK8 | P49336 | 1/20 | 0.31 |
| ▸ | ABL1 | P00519 | 1/20 | 0.31 |
| ▸ | SRC | P12931 | 1/20 | 0.31 |
| ▸ | P2RX3 | P56373 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20159274 | 0.88 | HTR2A (0.37) | ARMGLLPSEN1PSEN2APH1B | |
| SCHEMBL20159329 | 0.87 | PLA2G7 (0.40) | NR1H2NR1H3 | |
| SCHEMBL29623386 | 0.87 | PLA2G7 (0.40) | NR1H2NR1H3 | |
| SCHEMBL20138679 | 0.86 | AR (0.32) | ARS1PR1MGLL | |
| SCHEMBL20159971 | 0.85 | AR (0.33) | ARRHEBS1PR1ESR1MGLL | |
| SCHEMBL20138676 | 0.84 | ESR1 (0.30) | ESR1 | |
| SCHEMBL20154260 | 0.81 | LMNA (0.39) | PSEN1PSEN2APH1BNCSTNAPH1A | |
| SCHEMBL20142994 | 0.79 | MAPT (0.44) | MAPTPSEN1PSEN2APH1BNCSTN | |
| SCHEMBL20142954 | 0.78 | MAP4K4 (0.35) | MAPTPSEN1PSEN2APH1BNCSTN | |
| SCHEMBL20138669 | 0.78 | HTR2A (0.41) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-109790149-B | Phenoxytriazoles | 豪夫迈·罗氏有限公司 | 2022-05-17 | — | — | CN | disclosed |
| US-11319314-B2 | Phenoxytriazoles | HOFFMANN-LA ROCHE INC. (US) | 2022-05-03 | — | — | US | disclosed |
| US-11319314-B2 | Phenoxytriazoles | HOFFMANN-LA ROCHE INC. (US) | 2022-05-03 | — | — | US | disclosed |
| US-20210309653-A1 | PHENOXYTRIAZOLES | HOFFMANN-LA ROCHE INC. (US) | 2021-10-07 | — | — | US | disclosed |
| US-20210309653-A1 | PHENOXYTRIAZOLES | HOFFMANN-LA ROCHE INC. (US) | 2021-10-07 | — | — | US | disclosed |
| EP-3538516-B1 | PHENOXYTRIAZOLES | HOFFMANN LA ROCHE (CH) | 2021-06-16 | — | — | EP | disclosed |
| EP-3538516-B1 | PHENOXYTRIAZOLES | HOFFMANN LA ROCHE (CH) | 2021-06-16 | — | — | EP | disclosed |
| EP-3538516-A1 | PHENOXYTRIAZOLES | F. Hoffmann-La Roche AG (CH) | 2019-09-18 | — | — | EP | disclosed |
| WO-2018087018-A1 | PHENOXYTRIAZOLES | F. HOFFMANN-LA ROCHE AG (CH) | 2018-05-17 | — | — | WO | disclosed |
| WO-2018087018-A1 | PHENOXYTRIAZOLES | F. HOFFMANN-LA ROCHE AG (CH) | 2018-05-17 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210309653-A1 | PHENOXYTRIAZOLES | HTT, PSEN1, APP | AR 4377/4885RHEB 4150/4885S1PR1 443/4885 |
| US-11319314-B2 | Phenoxytriazoles | HTT, APP, PSEN1 | AR 4276/4885RHEB 3950/4885S1PR1 351/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.